Jiangsu Nhwa Pharmaceutical Co., LTD Stock

Equities

002262

CNE100000CG8

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
23.97 CNY +1.44% Intraday chart for Jiangsu Nhwa Pharmaceutical Co., LTD +3.77% -11.62%
Sales 2024 * 5.96B 823M Sales 2025 * 7.18B 991M Capitalization 24.15B 3.33B
Net income 2024 * 1.23B 170M Net income 2025 * 1.54B 213M EV / Sales 2024 * 3.54 x
Net cash position 2024 * 3.04B 420M Net cash position 2025 * 3.99B 551M EV / Sales 2025 * 2.81 x
P/E ratio 2024 *
19.6 x
P/E ratio 2025 *
15.7 x
Employees 5,394
Yield 2024 *
0.75%
Yield 2025 *
0.88%
Free-Float 48.19%
More Fundamentals * Assessed data
Dynamic Chart
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Nhwa Pharma Gets Nod to Test NH103 Oxalate Tablets MT
Jiangsu Nhwa Pharmaceutical Co., Ltd Proposes Profit Distribution for 2023 CI
Nhwa Pharmaceutical's 2023 Profit Climbs 15% as Revenue Rises 17% MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Monday Ahead of Data-Packed Week MT
Teva Pharmaceutical Investments Singapore Pte Ltd. and Jiangsu Nhwa Pharmaceutical Co., LTD Forge Strategic Partnership to Promote Patient Access to Austedo® in China CI
Nhwa Pharmaceutical Gets Green Light from US FDA After Addressing API Deficiencies MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Beijing Yihua M-Health Technology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Jiangsu Nhwa Pharmaceutical Co., LTD CI
Jiangsu Nhwa Pharmaceutical Co., LTD(XSEC:002262) added to FTSE All-World Index CI
Jiangsu Nhwa Pharma’s H1 Profit Jumps 21.7% as Revenue Rises 20% MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Wang Zeyu cancelled the acquisition of 13% stake in Jiangsu Farever Pharma Co., Ltd. from Jiangsu Nhwa Pharmaceutical Co., LTD. CI
Expected House Vote on Debt Ceiling Deal Weighs on Sentiment, Pushing US Equity Futures Lower MT
More news
1 day+1.44%
1 week+3.77%
Current month+7.01%
1 month+7.78%
3 months-4.58%
6 months-1.52%
Current year-11.62%
More quotes
1 week
22.81
Extreme 22.81
24.19
1 month
21.13
Extreme 21.13
24.19
Current year
20.64
Extreme 20.64
28.76
1 year
20.64
Extreme 20.64
31.98
3 years
10.97
Extreme 10.97
31.98
5 years
9.38
Extreme 9.38
31.98
10 years
7.59
Extreme 7.5855
31.98
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 10-05-25
Director of Finance/CFO 44 22-10-25
Director/Board Member 60 07-04-22
Members of the board TitleAgeSince
Chairman 65 07-04-22
Director/Board Member 62 07-04-22
Director/Board Member 61 07-04-22
More insiders
Date Price Change Volume
24-04-23 23.97 +1.44% 8 701 872
24-04-23 23.63 +1.46% 8,464,954
24-04-22 23.29 +0.04% 12,832,630
24-04-19 23.28 +0.52% 8,943,882
24-04-18 23.16 +0.17% 7,458,534

End-of-day quote Shenzhen S.E., April 23, 2024

More quotes
Jiangsu Nhwa Pharmaceutical Co., LTD is a China-based company principally engaged in the production and sales of pharmaceutical preparations. The Company offers its pharmaceutical products under four categories, which consist of anesthetic medicines, including midazolam injections and etomidate fat emulsion pharmaceutical preparations injections; psychiatric medicines, including risperidone tablets and others; neurological medicines, including gabapentin capsules and others; bulk drugs, including fenofibrate and miconazole nitrate. The Company is also engaged in the pharmaceuticals trading business. Through its subsidiaries, the Company is also engaged in the Internet medical businesses. The Company distributes its products within domestic market and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
23.97 CNY
Average target price
32.21 CNY
Spread / Average Target
+34.36%
Consensus
  1. Stock Market
  2. Equities
  3. 002262 Stock